Table 1.
Clinical characteristics of PTC patients from TCGA database according to MMP1 low or high expression.
| Characteristics | Low expression of MMP1 (n=255) | High expression of MMP1 (n=255) | P-value |
|---|---|---|---|
| Age, median (IQR) | 48 (36, 58) | 46 (34, 58) | 0.597 |
| Gender, n (%) | 0.029 | ||
| Female | 197 (38.6%) | 174 (34.1%) | |
| Male | 58 (11.4%) | 81 (15.9%) | |
| T stage, n (%) | 0.004 | ||
| T1 | 83 (16.3%) | 60 (11.8%) | |
| T2 | 82 (16.1%) | 85 (16.7%) | |
| T3 | 86 (16.9%) | 89 (17.5%) | |
| T4 | 4 (0.8%) | 19 (3.7%) | |
| N stage, n (%) | 0.005 | ||
| N0 | 127 (27.6%) | 102 (22.2%) | |
| N1 | 97 (21.1%) | 134 (29.1%) | |
| M stage, n (%) | 0.190 | ||
| M0 | 132 (44.7%) | 154 (52.2%) | |
| M1 | 2 (0.7%) | 7 (2.4%) | |
| Pathologic stage, n (%) | 0.291 | ||
| Stage I | 144 (28.3%) | 142 (28%) | |
| Stage II | 29 (5.7%) | 23 (4.5%) | |
| Stage III | 58 (11.4%) | 55 (10.8%) | |
| Stage IV | 22 (4.3%) | 35 (6.9%) | |
| Extrathyroidal extension, n (%) | 0.025 | ||
| No | 179 (36.4%) | 159 (32.3%) | |
| Yes | 64 (13%) | 90 (18.3%) | |
| Primary neoplasm focus type, n (%) | 0.720 | ||
| Multifocal | 119 (23.8%) | 114 (22.8%) | |
| Unifocal | 131 (26.2%) | 136 (27.2%) | |
| Histological type, n (%) | < 0.001 | ||
| Classical | 160 (31.4%) | 204 (40%) | |
| Follicular | 77 (15.1%) | 24 (4.7%) | |
| Other | 4 (0.8%) | 5 (1%) | |
| Tall Cell | 14 (2.7%) | 22 (4.3%) | |
| Thyroid gland disorder history, n (%) | < 0.001 | ||
| Lymphocytic Thyroiditis | 47 (10.4%) | 27 (6%) | |
| Nodular Hyperplasia | 47 (10.4%) | 21 (4.6%) | |
| Normal | 119 (26.3%) | 166 (36.7%) | |
| Other, specify | 12 (2.7%) | 13 (2.9%) |
Bold values show P < 0.05.
PTC, papillary thyroid cancer; TCGA, The Cancer Genome Atlas; IQR, interquartile range.